Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Haemonetics Corp Q2 2026 Results Show 19.7% Net Income Growth to $46.30 Million

Haemonetics Corporation achieved a 19.7% increase in net income for the second quarter of fiscal 2026, reaching $46.30 million. The results were supported by a 9.3% revenue rise and improved gross profit margins compared to the prior year.

Blood collection, material, blood collection tube, cannula. Stock photo illustrating Haemonetics' financial results story.
HAEMONETICS CORP · Photo: Myriams-Fotos / Pixabay
Results at a glance · $ Million
Metric Q2-26Q2-25
Revenue 357.76327.31
Gross Profit 220.91194.74
Pretax Income 62.8651.28
Net Income 46.3038.68
Diluted EPS 1.000.81
Net Income YoY
+19.7%

Key highlights

  • Net revenue grew 9.3% year-over-year to $357.76 million
  • Net income rose to $46.30 million, up from $38.68 million in the prior-year quarter
  • Diluted earnings per share increased to $1.00 from $0.81
  • Gross profit climbed to $220.91 million, representing significant margin expansion
  • Pretax income improved to $62.86 million compared to $51.28 million previously

How the Period Went

Haemonetics Corporation recorded a 9.3% increase in net revenue, reaching $357.76 million for the quarter ended September 26, 2026, compared to $327.31 million in the prior-year period. This top-line expansion translated into stronger profitability, as net income surged by 19.7% to $46.30 million. Diluted earnings per share followed this upward trajectory, rising from $0.81 to $1.00. Growth was primarily underpinned by higher gross profits and the absence of intangible asset impairments that had impacted the bottom line during the second quarter of fiscal 2025. The result marks a sequential improvement over the $339.38 million in revenue reported in the preceding quarter.

Margins and Profitability

Gross profit for the quarter rose to $220.91 million, a substantial improvement over the $194.74 million reported in the same period last year. This performance indicates a gross margin of approximately 61.7%, up from 59.5% year-over-year. Pretax income also demonstrated resilience, climbing to $62.86 million from $51.28 million. The margin expansion reflects a shift toward higher-margin products and operational efficiencies within the medical devices segment. Furthermore, the exclusion of one-time impairment costs, which weighed on previous results, bolstered the operating profile, allowing the company to convert a higher percentage of revenue into net earnings.

Business Overview

  • Core operations focus on blood management and hospital-based medical devices
  • Key segments include Plasma, Blood Center, and Hospital solutions
  • The Plasma segment is currently undergoing a nationwide U.S. transition of CSL Plasma centers to NexSys PCS devices
  • The company serves global end markets including blood collection centers and surgical suites
  • Transition of CSL Plasma centers to advanced technologies is targeted for completion by December 31, 2027

Financial Context

The Q2 2026 performance sits within a period of significant stock price appreciation, with Haemonetics shares rising 46.81% over the last quarter. This momentum has pushed the company's market capitalization to approximately $5.80 billion. With a price-to-earnings ratio of 61.56, the company is trading at a premium compared to many historical benchmarks. Technical indicators show a Relative Strength Index (RSI) of 75.2, suggesting the stock is currently in overbought territory. The steady revenue growth from $327.31 million to $357.76 million reflects the company's ability to maintain upward momentum as it cycles through major technology rollouts in its plasma division.

HAEMONETICS CORP share price · last month
Line chart of HAEMONETICS CORP's share price over the last month, from $118.73 on 19 Oct → $121.34 on 16 Nov; our story on 5 Nov at $127.42.

Down 4.8% since our story on 5 Nov: $127.42 when we broke it → $121.34 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$118.73
20 Oct$118.21
21 Oct$117.11
22 Oct$116.16
23 Oct$118.51
26 Oct$119.19
27 Oct$119.97
28 Oct$118.32
29 Oct$119.79
30 Oct$119.65
2 Nov$120.14
3 Nov$120.28
4 Nov$127.42
5 Nov$124.11
6 Nov$119.93
9 Nov$118.21
10 Nov$122.36
11 Nov$120.54
12 Nov$122.71
13 Nov$122.94
16 Nov$121.34

Industry Landscape

The medical device sector is experiencing a period of transformation as healthcare providers prioritize automated systems to improve procedural yields and mitigate labor constraints. Haemonetics operates in a competitive environment alongside firms like Terumo and Baxter, where success is increasingly tied to long-term hardware placement contracts and recurring software-enabled revenue. Demand for plasma-derived therapies continues to drive volume in the collection space, supporting the adoption of proprietary systems like the NexSys PCS. As the industry stabilizes following post-pandemic supply chain disruptions, focus has shifted toward operational efficiency and the integration of digital data management in blood collection workflows.

Recent quarters and guidance
DateAnnouncementAmount
06 Aug 2026Q1 FY2027 net revenue and raised FY2027 guidanceSource: SEC filing$339.4 Million
07 May 2026Q4 FY2026 net revenue and FY2027 guidanceSource: haemonetics.gcs-web.com$346.4 Million
05 Feb 2026Q3 FY2026 net revenue and raised FY2026 guidanceSource: SEC filing$339.0 Million
06 Nov 2025Q2 FY2026 net revenue and raised FY2026 guidanceSource: haemonetics.gcs-web.com$327.3 Million
07 Aug 2025Q1 FY2026 net revenue and reaffirmed FY2026 guidanceSource: haemonetics.gcs-web.com$321.4 Million
08 May 2025Q4 FY2025 net revenue and FY2026 guidanceSource: haemonetics.gcs-web.com$330.6 Million
HAEMONETICS CORP · financial snapshot
Share price$127.42
Market cap$5.8B
Revenue (annual)$1.3B
P/E (TTM)61.6×
1-month price change+21.72%
SectorHealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Haemonetics Corporation announcing financial results for the quarter ended September 26, 2026.

Read the filing ↗

Track HAEMONETICS CORP live

Get the next HAEMONETICS CORP SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.